ClinicalTrials.gg
CompletedNCT00516139Updated Jan 18, 2017Results posted

Lamotrigine Extended-Release In Elderly Patients With Epilepsy

A Phase 3 interventional study of Lamotrigine in Epilepsy, sponsored by GlaxoSmithKline. Completed at 63 sites in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2017-01-18.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
122
Allocation
Non-randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing lamotrigine in Epilepsy — 2 open to participants now, 2 under way, none of them phase 3. Lamotrigine · Epilepsy.

Enrollment
14th of 36
122 · median 76
Started
2007
with 2 others
Phase 3
12 of 36
none open now
Registered
17th of 36
by date
Lead sponsor
19 of 36
GlaxoSmithKline

Among the 36 studies testing lamotrigine in Epilepsy, this one is the 14th largest by enrollment, is one of 3 that started in 2007, is one of 12 in phase 3, and was the 17th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 36 studies testing lamotrigine in Epilepsy are open now. Recruiting first, the newest first:

All 2 open studies →

About lamotrigine

Lamotrigine: first FDA approval 1994 (LAMICTAL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing lamotrigine in Epilepsy, or all of them as a file.
02

Study summary

This study is being conducted to determine the safety and tolerability of lamotrigine (LTG) in elderly patients with epilepsy. This study will be carried out using an extended-release formulation of lamotrigine (LTG-XR) that will allow once-a-day dosing.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Epilepsy elderly seizure
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confident diagnosis of epilepsy
  • Currently treated with one or two antiepileptic medications
  • Able to complete a seizure diary

Exclusion criteria

Exclusion criteria:

  • History of to lamotrigine
  • Progressive diseases that would interfere with the study objectives
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    Lamotrigine

    Open-label lamotrigine

    Drug: Lamotrigine

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event

    An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or causes its prolongation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. A complete list of all SAEs and AEs experienced in the study can be found in the SAE/AE section.

    Time frame: From Baseline (Week 0) until 3 weeks after the end of treatment (Week 30 or 33)

Secondary outcomes

  1. Percent Change From Baseline (BL) in Weekly Seizure (sz.) Frequency for All Partial Seizures During Each Phase of the Study

    Partial-onset sz. have a focal site of onset; sz. activity is initially limited to 1 brain hemisphere. Partial sz. can remain simple or complex, or evolve to generalized tonic-clonic sz. Participants (par.) recorded the number of sz., by type as well as the episode duration of innumerable sz. activity), in daily diaries. If par. withdrew from study, data were averaged for the study portion the par. completed up to the time of drug discontinuation. Percent change from BL = (BL value minus study phase value divided by BL value) x 100; positive values indicate reduction from BL in sz. frequency.

    Time frame: Baseline (Week 0), Dose-Escalation Phase (Week 7), Maintenance Phase (Week 15), Adjunctive Optimization Phase (Week 28), Conversion Phase (Week 20), Monotherapy Phase (Week 28), and end of treatment (Week 30 or 33)

  2. Number of Participants With the Indicated Change From Baseline in Weekly Seizure Frequency During Each Phase of the Study

    Participants recorded the number of seizures, by seizure type, as well as the duration of episodes of innumerable seizure activity in their daily diaries during all phases of the study. For participants who withdrew from the study, seizure data were averaged for the portion of the study the participant completed up to the time of study drug discontinuation. Participants who experienced a change from Baseline in the weekly seizure frequency were categorized as having a \>=25%, \>=50%, \>=75%, or 100% reduction or a \>=50% increase in percent change from Baseline in weekly seizure frequency.

    Time frame: Baseline (Week 0), Dose-Escalation Phase (Week 7), Maintenance Phase (Week 15), Adjunctive Optimization (Adj O) Phase (Week 28), Conversion Phase (Week 20), Monotherapy Phase (Week 28), and end of treatment (ET, Week 30 or 33)

  3. Number of Seizure-free Participants at Baseline Who Remained Seizure-free Throughout the Entire Treatment Period

    Participants were considered to be seizure-free if they did not report any seizures at Baseline.

    Time frame: Week 30 or 33

  4. Number of Participants With Changes From Baseline in Seizure Severity in the Indicated Categories, as Measured by the Investigator's Global Evaluation (IGE) Scale

    Investigators rated the participants' seizure severity at Weeks 15 and 28 of the study treatment by using the IGE scale, comprised of 7 categories: 3 for improvement (mild improvement, moderate improvement, and marked improvement), 3 for deterioration (marked deterioration, moderate deterioration, mild deterioration), and 1 for no change. Investigators assessed the degree of the participants' improvement or deterioration or determined whether the participants' condition had not changed compared to their Baseline condition.

    Time frame: Week 15 (Adjunctive Maintenance [Adj M] Phase), Week 28 (Adjunctive Optimization [Adj O] Phase), Week 28 (Monotherapy [Mono] Phase), and Week 28 (Early Withdrawal [WD])

  5. Number of Participants With Changes From Baseline in Overall Clinical Status in the Indicated Categories, as Measured by the IGE Scale

    Investigators rated the participants' overall clinical status at Weeks 15 and 28 of the study treatment by using the IGE scale, comprised of 7 categories: 3 for improvement (mild improvement, moderate improvement, and marked improvement), 3 for deterioration (marked deterioration, moderate deterioration, mild deterioration), and 1 for no change. Investigators assessed the degree of the participants' improvement or deterioration or determined whether the participants' condition had not changed compared to their Baseline condition.

    Time frame: Week 15 (Adjunctive Maintenance [Adj M] Phase), Week 28 (Adjunctive Optimization [Adj O] Phase), Week 28 (Monotherapy [Mono] Phase), and Week 28 (Early Withdrawal [WD])

  6. Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at the Indicated Time Points in the Study

    Change from Baseline was calculated by subtracting the values of systolic and diastolic blood pressures recorded by the investigator at the indicated time points in the study from the respective Baseline values.

    Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), Week 28 (WD), and Week 30/33 (End of study [EOS])

  7. Change From Baseline in the Height at the Indicated Time Points in the Study

    Change from Baseline was calculated by subtracting the value of height measured by the investigator at the indicated time points in the study from the Baseline value.

    Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), Week 28 (WD), and Week 30/33 (End of study [EOS])

  8. Change From Baseline in the Weight at the Indicated Time Points in the Study

    Change from Baseline was calculated by subtracting the value of weight measured by the investigator at the indicated time points in the study from the Baseline value.

    Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), Week 28 (WD), and Week 30/33 (End of study [EOS])

  9. Change From Baseline in the Basophil, Eosinophil, Hemoglobin, Lymphocyte, Monocyte, Absolute Neutrophil Count (ANC), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points in the Study

    The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of basophil, eosinophil, hemoglobin, lymphocyte, monocyte, ANC, platelet count, and WBC count at the indicated time points in the study from the Baseline value.

    Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)

  10. Percent Change From Baseline in the Basophil, Eosinophil, Hemoglobin, Lymphocyte, Monocyte, Absolute Neutrophil Count, Platelet Count, and White Blood Cell Count at the Indicated Time Points in the Study

    The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Percent change from Baseline = (value at each indicated time point in the study minus respective Baseline value divided by Baseline value) x 100.

    Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)

  11. Change From Baseline in the Mean Corpuscle Hemoglobin Concentration (MCHC), Albumin, and Total Protein at the Indicated Time Points in the Study

    The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the values of MCHC, albumin, and total protein at the indicated time points in the study from the respective Baseline values.

    Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)

  12. Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at the Indicated Time Points in the Study

    The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of MCH at the indicated time points in the study from the Baseline value.

    Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)

  13. Change From Baseline in Mean Corpuscle Volume (MCV) at the Indicated Time Points in the the Study

    The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of MCV at the indicated time points in the study from the Baseline value.

    Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)

  14. Change From Baseline in Red Blood Cell (RBC) Count at the Indicated Time Points in the Study

    The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of RBC count at the indicated time points in the study from the Baseline value. Change from baseline is measured as the number of red blood cells x 10\^12 per liter.

    Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)

  15. Change From Baseline in Alkaline Phosphatase (Alk P), Alanine Amino Transferase (Ala AT), and Aspartate Amino Transferase (Asp AT) at the Indicated Time Points in the Study

    The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of Alk P, Ala AT, and Asp AT at the indicated time points in the study from the Baseline value.

    Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)

  16. Change From Baseline in Direct Bilirubin (DB), Total Bilirubin (TB), and Creatinine at the Indicated Time Points in the Study

    The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of DB, TB, and creatinine at the indicated time points in the study from the Baseline value.

    Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)

  17. Change From Baseline in Cholesterol, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Glucose, Potassium, Sodium, Triglycerides, and Urea/Blood Urea Nitrogen (BUN) at the Indicated Time Points

    The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of cholesterol, HDL cholesterol, LDL cholesterol, glucose, potassium, sodium, triglycerides, and urea/BUN at the indicated time points in the study from the Baseline value.

    Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)

  18. Serum LTG Concentrations at Different LTG Doses Based on the Concomitant AED Groups: Neutral (Without Known Enzyme-inducing AED [EIAED], Valproate [VPA]) With EIAED, and With VPA

    The blood samples were collected at the specified study visits; however, serum LTG concentrations were summarized by dose regimen, not by study week. The serum was assayed for LTG using an approved method under the management of Worldwide Bioanalysis, GlaxoSmithKline.

    Time frame: Weeks 4, 7, 11, 15, 20, 24, and 28

  19. Apparent Clearance (CL/F) Based on the Concomitant AED Groups: Neutral, With EIAED, and With VPA

    Individual serum LTG concentration data were subjected to population pharmacokinetic methodologies based on the concomitant AED groups. Clearance is defined as the volume of LTG per unit time eliminated from serum. Serum LTG concentration-time data files incorporating, where appropriate, records of LTG administration, participant demography, and concomitant medication were supplied to Clinical Pharmacokinetics Modelling and Simulation, Clinical Pharmacology, and Discovery Medicine (CPDM) by Clinical Data Management as NONMEM compatible .csv files.

    Time frame: Weeks 4, 7, 11, 15, 20, 24, and 28

  20. Apparent Volume of Distribution (V/F) for Participants in All Concomitant AED Groups Combined: Neutral, With EIAED, and With VPA

    Individual serum LTG concentration data were subjected to population pharmacokinetic methodologies based on the concomitant AED groups. V/F is defined as the apparent volume in which a drug is distributed immediately after it has been injected intravenously and equilibrated between plasma and the surrounding tissues. Serum LTG concentration-time data files incorporating, where appropriate, records of LTG administration, participant demography, and concomitant medication were supplied to CPDM by Clinical Data Management as NONMEM compatible .csv files.

    Time frame: Weeks 4, 7, 11, 15, 20, 24, and 28

  21. Absorption Rate (KA) for Participants in All Concomitant AED Groups Combined: Neutral, With EIAED, and With VPA

    Individual serum LTG concentration data were subjected to population pharmacokinetic methodologies based on the concomitant AED groups. KA is defined as the rate at which a drug enters the body after administration. Serum LTG concentration-time data files incorporating, where appropriate, records of LTG administration, participant demography, and concomitant medication were supplied to CPDM by Clinical Data Management as NONMEM compatible .csv files.

    Time frame: Weeks 4, 7, 11, 15, 20, 24, and 28

07

Results

Posted Jan 13, 2012

Participant flow

Participant flow — Overall Study
MilestoneLamotrigine (LTG)-Extended Release (XR) Tablets
Started122
Completed84
Not completed38
Withdrew: Adverse event27
Withdrew: Lost to follow-up1
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject8
Withdrew: Lack of efficacy1

Outcome measures

PrimaryNumber of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event

An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or causes its prolongation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. A complete list of all SAEs and AEs experienced in the study can be found in the SAE/AE section.

Time frame:
From Baseline (Week 0) until 3 weeks after the end of treatment (Week 30 or 33)
Reported as:
Number · participants
Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event
participantsLTG-XR Tablets
Participants with any SAE22
Participants with any non-serious AE112
SecondaryPercent Change From Baseline (BL) in Weekly Seizure (sz.) Frequency for All Partial Seizures During Each Phase of the Study

Partial-onset sz. have a focal site of onset; sz. activity is initially limited to 1 brain hemisphere. Partial sz. can remain simple or complex, or evolve to generalized tonic-clonic sz. Participants (par.) recorded the number of sz., by type as well as the episode duration of innumerable sz. activity), in daily diaries. If par. withdrew from study, data were averaged for the study portion the par. completed up to the time of drug discontinuation. Percent change from BL = (BL value minus study phase value divided by BL value) x 100; positive values indicate reduction from BL in sz. frequency.

Time frame:
Baseline (Week 0), Dose-Escalation Phase (Week 7), Maintenance Phase (Week 15), Adjunctive Optimization Phase (Week 28), Conversion Phase (Week 20), Monotherapy Phase (Week 28), and end of treatment (Week 30 or 33)
Reported as:
Median · Percent change in seizure frequency
Percent Change From Baseline (BL) in Weekly Seizure (sz.) Frequency for All Partial Seizures During Each Phase of the Study
Percent change in seizure frequencyLTG-XR Tablets
Dose-Escalation Phase (Week 7), n=5597.8 (-146.3 to 100.0)
Maintenance Phase (Week 15), n=43100.0 (-162.5 to 100.0)
Adjunctive Optimization Phase (Week 28), n=15100.0 (33.3 to 100.0)
Conversion Phase (Week 20), n=24100.0 (-44.5 to 100.0)
Monotherapy Phase (Week 28), n=24100.0 (-269.8 to 100.0)
End Of Treatment (Week 30/33), n=5590.4 (-86.7 to 100.0)
SecondaryNumber of Participants With the Indicated Change From Baseline in Weekly Seizure Frequency During Each Phase of the Study

Participants recorded the number of seizures, by seizure type, as well as the duration of episodes of innumerable seizure activity in their daily diaries during all phases of the study. For participants who withdrew from the study, seizure data were averaged for the portion of the study the participant completed up to the time of study drug discontinuation. Participants who experienced a change from Baseline in the weekly seizure frequency were categorized as having a \>=25%, \>=50%, \>=75%, or 100% reduction or a \>=50% increase in percent change from Baseline in weekly seizure frequency.

Time frame:
Baseline (Week 0), Dose-Escalation Phase (Week 7), Maintenance Phase (Week 15), Adjunctive Optimization (Adj O) Phase (Week 28), Conversion Phase (Week 20), Monotherapy Phase (Week 28), and end of treatment (ET, Week 30 or 33)
Reported as:
Number · participants
Number of Participants With the Indicated Change From Baseline in Weekly Seizure Frequency During Each Phase of the Study
participantsLTG-XR Tablets
Dose-Escalation (Week 7), >=25% reduction, n=5549
Dose-Escalation (Week 7), >=50% reduction, n=5541
Dose-Escalation (Week 7), >=75% reduction, n=5530
Dose-Escalation (Week 7), 100% reduction, n=5527
Dose-Escalation (Week 7), >=50% increase, n=552
Maintenance (Week 15), >=25% reduction, n=4339
Maintenance (Week 15), >=50% reduction, n=4337
Maintenance (Week 15), >=75% reduction, n=4333
Maintenance (Week 15), 100% reduction, n=4330
Maintenance (Week 15), >=50% increase, n=432
Adj O (Week 28), >=25% reduction, n=1515
Adj O (Week 28), >=50% reduction, n=1514
Adj O (Week 28), >=75% reduction, n=1512
Adj O (Week 28), 100% reduction, n=1511
Adj O (Week 28), >=50% increase, n=150
Conversion (Week 20), >=25% reduction, n=2423
Conversion (Week 20), >=50% reduction, n=2423
Conversion (Week 20), >=75% reduction, n=2419
Conversion (Week 20), 100% reduction, n=2417
Conversion (Week 20), >=50% increase, n=240
Monotherapy (Week 28), >=25% reduction, n=2423
Monotherapy (Week 28), >=50% reduction, n=2420
Monotherapy (Week 28), >=75% reduction, n=2417
Monotherapy (Week 28), 100% reduction, n=2413
Monotherapy (Week 28), >=50% increase, n=241
ET (Week 30/33), >=25% reduction, n=5547
ET (Week 30/33), >=50% reduction, n=5544
ET (Week 30/33), >=75% reduction, n=5536
ET (Week 30/33), 100% reduction, n=5524
ET (Week 30/33), >=50% increase, n=551
SecondaryNumber of Seizure-free Participants at Baseline Who Remained Seizure-free Throughout the Entire Treatment Period

Participants were considered to be seizure-free if they did not report any seizures at Baseline.

Time frame:
Week 30 or 33
Reported as:
Number · participants
Number of Seizure-free Participants at Baseline Who Remained Seizure-free Throughout the Entire Treatment Period
participantsLTG-XR Tablets
Remained Seizure-Free53
Did Not Remain Seizure-Free13
SecondaryNumber of Participants With Changes From Baseline in Seizure Severity in the Indicated Categories, as Measured by the Investigator's Global Evaluation (IGE) Scale

Investigators rated the participants' seizure severity at Weeks 15 and 28 of the study treatment by using the IGE scale, comprised of 7 categories: 3 for improvement (mild improvement, moderate improvement, and marked improvement), 3 for deterioration (marked deterioration, moderate deterioration, mild deterioration), and 1 for no change. Investigators assessed the degree of the participants' improvement or deterioration or determined whether the participants' condition had not changed compared to their Baseline condition.

Time frame:
Week 15 (Adjunctive Maintenance [Adj M] Phase), Week 28 (Adjunctive Optimization [Adj O] Phase), Week 28 (Monotherapy [Mono] Phase), and Week 28 (Early Withdrawal [WD])
Reported as:
Number · participants
Number of Participants With Changes From Baseline in Seizure Severity in the Indicated Categories, as Measured by the Investigator's Global Evaluation (IGE) Scale
participantsLTG-XR Tablets
Week 15, Adj M Phase, Improvement, n=9136
Week 15, Adj M Phase, No change, n=9154
Week 15, Adj M Phase, Deterioration, n=911
Week 28, Adj O Phase, Improvement, n=2113
Week 28, Adj O Phase, No change, n=217
Week 28, Adj O Phase, Deterioration, n=211
Week 28, Mono Phase, Improvement, n=6329
Week 28, Mono Phase, No change, n=6333
Week 28, Mono Phase, Deterioration, n=631
Week 28, WD, Improvement, n=357
Week 28, WD, No change, n=3525
Week 28, WD, Deterioration, n=353
SecondaryNumber of Participants With Changes From Baseline in Overall Clinical Status in the Indicated Categories, as Measured by the IGE Scale

Investigators rated the participants' overall clinical status at Weeks 15 and 28 of the study treatment by using the IGE scale, comprised of 7 categories: 3 for improvement (mild improvement, moderate improvement, and marked improvement), 3 for deterioration (marked deterioration, moderate deterioration, mild deterioration), and 1 for no change. Investigators assessed the degree of the participants' improvement or deterioration or determined whether the participants' condition had not changed compared to their Baseline condition.

Time frame:
Week 15 (Adjunctive Maintenance [Adj M] Phase), Week 28 (Adjunctive Optimization [Adj O] Phase), Week 28 (Monotherapy [Mono] Phase), and Week 28 (Early Withdrawal [WD])
Reported as:
Number · participants
Number of Participants With Changes From Baseline in Overall Clinical Status in the Indicated Categories, as Measured by the IGE Scale
participantsLTG-XR Tablets
Week 15, Adj M Phase, Improvement, n=9151
Week 15, Adj M Phase, No change, n=9129
Week 15, Adj M Phase, Deterioration, n=9111
Week 28, Adj O Phase, Improvement, n=2117
Week 28, Adj O Phase, No change, n=212
Week 28, Adj O Phase, Deterioration, n=212
Week 28, Mono Phase, Improvement, n=6343
Week 28, Mono Phase, No change, n=6314
Week 28, Mono Phase, Deterioration, n=636
Week 28, WD, Improvement, n=357
Week 28, WD, No change, n=3512
Week 28, WD, Deterioration, n=3516
SecondaryChange From Baseline in Systolic and Diastolic Blood Pressure (BP) at the Indicated Time Points in the Study

Change from Baseline was calculated by subtracting the values of systolic and diastolic blood pressures recorded by the investigator at the indicated time points in the study from the respective Baseline values.

Time frame:
Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), Week 28 (WD), and Week 30/33 (End of study [EOS])
Reported as:
Mean · Millimeters of mercury
Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at the Indicated Time Points in the Study
Millimeters of mercuryLTG-XR Tablets
Systolic BP, Week 15, Adj M Phase, n=881.51 ± 19.038
Systolic BP, Week 28, Adj O Phase, n=21-0.62 ± 15.377
Systolic BP, Week 28, Mono Phase, n=630.68 ± 20.509
Systolic BP, Week 28, WD, n=35-4.00 ± 15.566
Systolic BP, Week 30/33, EOS, n=119-2.19 ± 15.928
Diastolic BP, Week 15, Adj M Phase, n=88-1.22 ± 10.547
Diastolic BP, Week 28, Adj O Phase, n=21-1.05 ± 7.214
Diastolic BP, Week 28, Mono Phase, n=63-0.08 ± 10.754
Diastolic BP, Week 28, WD, n=35-2.09 ± 8.763
Diastolic BP, Week 30/33, EOS, n=119-2.07 ± 9.102
SecondaryChange From Baseline in the Height at the Indicated Time Points in the Study

Change from Baseline was calculated by subtracting the value of height measured by the investigator at the indicated time points in the study from the Baseline value.

Time frame:
Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), Week 28 (WD), and Week 30/33 (End of study [EOS])
Reported as:
Mean · centimeters
Change From Baseline in the Height at the Indicated Time Points in the Study
centimetersLTG-XR Tablets
Week 15, Adj M Phase, n=900.03 ± 1.302
Week 28, Adj O Phase, n=210.29 ± 2.217
Week 28, Mono Phase, n=62-0.03 ± 1.293
Week 28, WD, n=36-0.03 ± 1.028
Week 30/33, EOS, n=1200.03 ± 1.417
SecondaryChange From Baseline in the Weight at the Indicated Time Points in the Study

Change from Baseline was calculated by subtracting the value of weight measured by the investigator at the indicated time points in the study from the Baseline value.

Time frame:
Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), Week 28 (WD), and Week 30/33 (End of study [EOS])
Reported as:
Mean · kilograms
Change From Baseline in the Weight at the Indicated Time Points in the Study
kilogramsLTG-XR Tablets
Week 15, Adj M Phase, n=88-0.22 ± 3.204
Week 28, Adj O Phase, n=21-0.41 ± 2.968
Week 28, Mono Phase, n=62-0.48 ± 3.520
Week 28, WD, n=36-0.27 ± 3.735
Week 30/33, EOS, n=119-0.41 ± 3.470
SecondaryChange From Baseline in the Basophil, Eosinophil, Hemoglobin, Lymphocyte, Monocyte, Absolute Neutrophil Count (ANC), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points in the Study

The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of basophil, eosinophil, hemoglobin, lymphocyte, monocyte, ANC, platelet count, and WBC count at the indicated time points in the study from the Baseline value.

Time frame:
Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)
Reported as:
Median · Giga (10^9) cells per liter
Change From Baseline in the Basophil, Eosinophil, Hemoglobin, Lymphocyte, Monocyte, Absolute Neutrophil Count (ANC), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points in the Study
Giga (10^9) cells per literLTG-XR Tablets
Basophil, Week 15, Adj M, n=850.00 (-0.03 to 0.06)
Basophil, Week 28, Adj O, n=190.00 (-0.02 to 0.02)
Basophil, Week 28, Mono, n=550.00 (-0.05 to 0.05)
Basophil, Week 28, WD, n=330.00 (-0.04 to 0.04)
Eosinophil, Week 15, Adj M, n=890.00 (-0.38 to 0.55)
Eosinophil, Week 28, Adj O, n=210.01 (-0.06 to 0.26)
Eosinophil, Week 28, Mono, n=610.01 (-0.23 to 0.54)
Eosinophil, Week 28, WD, n=33-0.01 (-0.17 to 0.84)
Hemoglobin, Week 15, Adj M, n=85-4.00 (-38.00 to 19.00)
Hemoglobin, Week 28, Adj O, n=19-6.00 (-22.00 to 4.00)
Hemoglobin, Week 28, Mono, n=55-4.00 (-25.00 to 10.00)
Hemoglobin, Week 28, WD, n=33-2.00 (-21.00 to 31.00)
Lymphocytes, Week 15, Adj M, n=85-0.12 (-1.55 to 1.52)
Lymphocytes, Week 28, Adj O, n=19-0.05 (-0.61 to 0.40)
Lymphocytes, Week 28, Mono, n=55-0.20 (-1.75 to 0.62)
Lymphocytes, Week 28, WD, n=33-0.09 (-0.94 to 0.66)
Monocytes, Week 15, Adj M, n=85-0.03 (-0.41 to 0.47)
Monocytes, Week 28, Adj O, n=190.00 (-0.55 to 0.26)
Monocytes, Week 28, Mono, n=55-0.04 (-0.37 to 0.40)
Monocytes, Week 28, WD, n=33-0.01 (-0.48 to 0.64)
Absolute Neutrophil Count, Week 15, Adj M, n=85-0.23 (-3.00 to 5.04)
Absolute Neutrophil Count, Week 28, Adj O, n=190.09 (-2.17 to 3.31)
Absolute Neutrophil Count, Week 28, Mono, n=55-0.17 (-3.18 to 2.71)
Absolute Neutrophil Count, Week 28, WD, n=330.17 (-1.99 to 6.47)
Platelet Count, Week 15, Adj M, n=841.50 (-91.00 to 226.00)
Platelet Count, Week 28, Adj O, n=193.00 (-55.00 to 216.00)
Platelet Count, Week 28, Mono, n=540.00 (-75.00 to 104.00)
Platelet Count, Week 28, WD, n=326.50 (-80.00 to 172.00)
White Blood Cell Count, Week 15, Adj M, n=85-0.30 (-2.80 to 5.70)
White Blood Cell Count, Week 28, Adj O, n=19-0.20 (-2.40 to 3.20)
White Blood Cell Count, Week 28, Mono, n=55-0.60 (-3.50 to 2.00)
White Blood Cell Count, Week 28, WD, n=330.30 (-2.20 to 6.00)
SecondaryPercent Change From Baseline in the Basophil, Eosinophil, Hemoglobin, Lymphocyte, Monocyte, Absolute Neutrophil Count, Platelet Count, and White Blood Cell Count at the Indicated Time Points in the Study

The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Percent change from Baseline = (value at each indicated time point in the study minus respective Baseline value divided by Baseline value) x 100.

Time frame:
Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)
Reported as:
Median · Percent change in counts
Percent Change From Baseline in the Basophil, Eosinophil, Hemoglobin, Lymphocyte, Monocyte, Absolute Neutrophil Count, Platelet Count, and White Blood Cell Count at the Indicated Time Points in the Study
Percent change in countsLTG-XR Tablets
Basophil, Week 15, Adj M, n=890.00 (-0.80 to 1.00)
Basophil, Week 28, Adj O, n=210.00 (-0.50 to 0.50)
Basophil, Week 28, Mono, n=610.00 (-0.80 to 0.90)
Basophil, Week 28, WD, n=330.00 (-0.50 to 0.90)
Eosinophil, Week 15, Adj M, n=890.20 (-4.40 to 10.90)
Eosinophil, Week 28, Adj O, n=210.10 (-1.50 to 4.30)
Eosinophil, Week 28, Mono, n=610.30 (-3.30 to 10.80)
Eosinophil, Week 28, WD, n=33-0.20 (-2.90 to 17.60)
Hematocrit, Week 15, Adj M, n=85-0.01 (-0.11 to 0.06)
Hematocrit, Week 28, Adj O, n=19-0.02 (-0.07 to 0.02)
Hematocrit, Week 28, Mono, n=55-0.01 (-0.09 to 0.04)
Hematocrit, Week 28, WD, n=33-0.00 (-0.04 to 0.10)
Lymphocytes, Week 15, Adj M, n=89-2.10 (-25.80 to 18.90)
Lymphocytes, Week 28, Adj O, n=21-2.40 (-16.00 to 13.60)
Lymphocytes, Week 28, Mono, n=61-1.50 (-23.90 to 12.40)
Lymphocytes, Week 28, WD, n=33-1.60 (-14.20 to 8.10)
Monocytes, Week 15, Adj M, n=890.00 (-8.90 to 6.50)
Monocytes, Week 28, Adj O, n=210.10 (-10.90 to 5.10)
Monocytes, Week 28, Mono, n=61-0.20 (-6.40 to 9.50)
Monocytes, Week 28, WD, n=33-0.30 (-8.00 to 8.10)
Total Neutrophils, Week 15, Adj M, n=891.3 (-26.30 to 30.40)
Total Neutrophils, Week 28, Adj O, n=210.50 (-13.80 to 16.80)
Total Neutrophils, Week 28, Mono, n=610.50 (-13.80 to 24.20)
Total Neutrophils, Week 28, WD, n=331.20 (-12.00 to 19.20)
SecondaryChange From Baseline in the Mean Corpuscle Hemoglobin Concentration (MCHC), Albumin, and Total Protein at the Indicated Time Points in the Study

The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the values of MCHC, albumin, and total protein at the indicated time points in the study from the respective Baseline values.

Time frame:
Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)
Reported as:
Median · grams per liter
Change From Baseline in the Mean Corpuscle Hemoglobin Concentration (MCHC), Albumin, and Total Protein at the Indicated Time Points in the Study
grams per literLTG-XR Tablets
MCHC, Week 15, Adj M, n=85-4.00 (-30.00 to 27.00)
MCHC, Week 28, Adj O, n=211.00 (-18.00 to 26.00)
MCHC, Week 28, Mono, n=61-5.00 (-31.00 to 24.00)
MCHC, Week 28, WD, n=331.00 (-25.00 to 15.00)
Albumin, Week 15, Adj M, n=870.00 (-5.00 to 7.00)
Albumin, Week 28, Adj O, n=20-1.00 (-8.00 to 3.00)
Albumin, Week 28, Mono, n=610.00 (-6.00 to 6.00)
Albumin, Week 28, WD, n=330.00 (-9.00 to 6.00)
Total Protein, Week 15, WD, n=87-1.0 (-13.0 to 8.0)
Total Protein, Week 28, WD, n=20-3.00 (-11.0 to 3.0)
Total Protein, Week 28, WD, n=61-1.0 (-15.0 to 6.0)
Total Protein, Week 28, WD, n=33-1.0 (-15.0 to 7.0)
SecondaryChange From Baseline in Mean Corpuscle Hemoglobin (MCH) at the Indicated Time Points in the Study

The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of MCH at the indicated time points in the study from the Baseline value.

Time frame:
Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)
Reported as:
Median · picograms
Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at the Indicated Time Points in the Study
picogramsLTG-XR Tablets
Week 15, Adj M, n=85-0.10 (-3.30 to 2.60)
Week 28, Adj O, n=190.10 (-1.20 to 1.60)
Week 28, Mono, n=55-0.20 (-2.30 to 1.40)
Week 28, WD, n=33-0.20 (-1.90 to 3.50)
SecondaryChange From Baseline in Mean Corpuscle Volume (MCV) at the Indicated Time Points in the the Study

The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of MCV at the indicated time points in the study from the Baseline value.

Time frame:
Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)
Reported as:
Median · Femtoliters
Change From Baseline in Mean Corpuscle Volume (MCV) at the Indicated Time Points in the the Study
FemtolitersLTG-XR Tablets
Week 15, Adj M, n=850.00 (-7.00 to 9.00)
Week 28, Adj O, n=19-1.00 (-7.00 to 5.00)
Week 28, Mono, n=551.00 (-9.00 to 7.00)
Week 28, WD, n=330.00 (-4.00 to 12.00)
SecondaryChange From Baseline in Red Blood Cell (RBC) Count at the Indicated Time Points in the Study

The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of RBC count at the indicated time points in the study from the Baseline value. Change from baseline is measured as the number of red blood cells x 10\^12 per liter.

Time frame:
Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)
Reported as:
Median · Tera (10^12) cells per liter
Change From Baseline in Red Blood Cell (RBC) Count at the Indicated Time Points in the Study
Tera (10^12) cells per literLTG-XR Tablets
Week 15, Adj M, n=85-0.10 (-0.90 to 0.40)
Week 28, Adj O, n=19-0.20 (-0.80 to 0.10)
Week 28, Mono, n=55-0.10 (-0.70 to 0.40)
Week 28, WD, n=330.00 (-0.50 to 1.00)
SecondaryChange From Baseline in Alkaline Phosphatase (Alk P), Alanine Amino Transferase (Ala AT), and Aspartate Amino Transferase (Asp AT) at the Indicated Time Points in the Study

The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of Alk P, Ala AT, and Asp AT at the indicated time points in the study from the Baseline value.

Time frame:
Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)
Reported as:
Median · International units per liter
Change From Baseline in Alkaline Phosphatase (Alk P), Alanine Amino Transferase (Ala AT), and Aspartate Amino Transferase (Asp AT) at the Indicated Time Points in the Study
International units per literLTG-XR Tablets
Alk P, Week 15, Adj M, n=871.00 (-86.0 to 141.00)
Alk P, Week 28, Adj O, n=20-0.50 (-72.0 to 20.0)
Alk P, Week 28, Mono, n=61-5.0 (-118.0 to 49.0)
Alk P, Week 28, WD, n=332.00 (-90.0 to 90.00)
Ala-AT Week 15, Adj M, n=87-2.00 (-30.0 to 71.0)
Ala-AT, Week 28, Adj O, n=20-1.0 (-10.0 to 23.0)
Ala-AT, Week 28, Mono, n=61-2.0 (-32.0 to 55.0)
Ala-AT, Week 28, WD, n=33-2.0 (-20.0 to 7.0)
Asp-AT, Week 15, Adj M, n=87-1.0 (-19.0 to 47.0)
Asp-AT, Week 28, WD, n=32-3.0 (-34.0 to 7.0)
Asp-AT, Week 28, Adj O, n=20-2.0 (-13.0 to 18.0)
Asp-AT, Week 28, Mono, n=600.00 (-15.0 to 17.0)
SecondaryChange From Baseline in Direct Bilirubin (DB), Total Bilirubin (TB), and Creatinine at the Indicated Time Points in the Study

The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of DB, TB, and creatinine at the indicated time points in the study from the Baseline value.

Time frame:
Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)
Reported as:
Median · micromoles (µmol) per liter
Change From Baseline in Direct Bilirubin (DB), Total Bilirubin (TB), and Creatinine at the Indicated Time Points in the Study
micromoles (µmol) per literLTG-XR Tablets
DB, Week 15, Adj M, n=870.0 (-1.7 to 6.8)
DB, Week 28, Adj O, n=200.0 (-3.4 to 1.7)
DB, Week 28, Mono, n=610.0 (-1.7 to 12.0)
DB, Week 28, WD, n=330.0 (-1.7 to 1.7)
TB, Week 15, Adj M, n=880.0 (-8.6 to 15.4)
TB, Week 28, Adj O, n=200.0 (-3.4 to 1.7)
TB, Week 28, Mono, n=611.7 (-8.6 to 12.0)
TB, Week 28, WD, n=330.0 (-3.4 to 5.1)
Creatinine, Week 15, Adj M, n=888.8 (-17.7 to 53.0)
Creatinine, Week 28, Adj O, n=208.8 (0.0 to 203.3)
Creatinine, Week 28, Mono, n=618.8 (-17.7 to 53.0)
Creatinine, Week 28, WD, n=330.0 (-17.7 to 17.7)
SecondaryChange From Baseline in Cholesterol, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Glucose, Potassium, Sodium, Triglycerides, and Urea/Blood Urea Nitrogen (BUN) at the Indicated Time Points

The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of cholesterol, HDL cholesterol, LDL cholesterol, glucose, potassium, sodium, triglycerides, and urea/BUN at the indicated time points in the study from the Baseline value.

Time frame:
Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)
Reported as:
Median · millimoles (mmol) per liter
Change From Baseline in Cholesterol, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Glucose, Potassium, Sodium, Triglycerides, and Urea/Blood Urea Nitrogen (BUN) at the Indicated Time Points
millimoles (mmol) per literLTG-XR Tablets
Cholesterol, Week 15, Adj M, n=87-0.1 (-1.7 to 1.7)
Cholesterol, Week 28, Adj O, n=20-0.1 (-2.2 to 0.9)
Cholesterol, Week 28, Mono, n=61-0.3 (-2.5 to 1.2)
Cholesterol, Week 28, WD, n=33-0.1 (-3.5 to 1.0)
HDL Cholesterol, Week 15, Adj M, n=870.1 (-1.0 to 0.6)
HDL Cholesterol, Week 28, Adj O, n=20-0.0 (-0.4 to 0.6)
HDL Cholesterol, Week 28, Mono, n=610.0 (-0.7 to 0.7)
HDL Cholesterol, Week 28, WD, n=330.1 (-0.9 to 0.4)
LDL Cholesterol, Week 15, Adj M, n=86-0.0 (-1.1 to 1.2)
LDL Cholesterol, Week 28, Adj O, n=19-0.2 (-1.9 to 1.1)
LDL Cholesterol, Week 28, Mono, n=61-0.1 (-1.8 to 1.6)
LDL Cholesterol, Week 28, WD, n=32-0.1 (-0.8 to 1.7)
Glucose, Week 15, Adj M, n=87-0.1 (-5.8 to 5.3)
Glucose, Week 28, Adj O, n=200.1 (-6.7 to 6.7)
Glucose, Week 28, Mono, n=610.1 (-3.6 to 6.4)
Glucose, Week 28, WD, n=330.3 (-5.2 to 4.2)
Potassium, Week 15, Adj M, n=870.0 (-1.2 to 1.1)
Potassium, Week 28, Adj O, n=20-0.1 (-0.7 to 1.2)
Potassium, Week 28, Mono, n=600.0 (-1.3 to 1.2)
Potassium, Week 28, WD, n=320.0 (-1.0 to 0.9)
Sodium, Week 15, Adj M, n=870.0 (-4.0 to 6.0)
Sodium, Week 28, Adj O, n=200.5 (-7.0 to 4.0)
Sodium, Week 28, Mono, n=61-1.0 (-5.0 to 9.0)
Sodium, Week 28, WD, n=331.0 (-3.0 to 7.0)
Triglyceride, Week 28, WD, n=87-0.3 (-2.3 to 0.9)
Triglyceride, Week 28, WD, n=20-0.1 (-1.7 to 1.6)
Triglyceride, Week 28, WD, n=61-0.4 (-1.9 to 1.1)
Triglyceride, Week 28, WD, n=331.0 (-4.6 to 1.1)
Urea/BUN, Week 28, WD, n=870.0 (-10.4 to 5.4)
Urea/BUN, Week 28, WD, n=200.5 (-2.1 to 13.2)
Urea/BUN, Week 28, WD, n=610.0 (-6.4 to 6.8)
Urea/BUN, Week 28, WD, n=330.4 (-4.3 to 3.6)
SecondarySerum LTG Concentrations at Different LTG Doses Based on the Concomitant AED Groups: Neutral (Without Known Enzyme-inducing AED [EIAED], Valproate [VPA]) With EIAED, and With VPA

The blood samples were collected at the specified study visits; however, serum LTG concentrations were summarized by dose regimen, not by study week. The serum was assayed for LTG using an approved method under the management of Worldwide Bioanalysis, GlaxoSmithKline.

Time frame:
Weeks 4, 7, 11, 15, 20, 24, and 28
Reported as:
Median · Micrograms per milliliter
Serum LTG Concentrations at Different LTG Doses Based on the Concomitant AED Groups: Neutral (Without Known Enzyme-inducing AED [EIAED], Valproate [VPA]) With EIAED, and With VPA
Micrograms per milliliterLTG-XR + NeutralLTG-XR + EIAEDsLTG-XR + VPA
12.5 mg, n=0, 0, 1NA (NA to NA)NA (NA to NA)0.957 (NA to NA)
25 mg, n=0, 0, 8NA (NA to NA)NA (NA to NA)1.362 (0.817 to 2.885)
50 mg, n=30, 2, 81.281 (0.437 to 3.491)0.731 (0.727 to 0.734)2.972 (0.937 to 3.553)
100 mg, n=40, 32, 63.425 (0.717 to 5.825)1.165 (0.442 to 4.254)4.723 (3.870 to 6.419)
150 mg, n=11, 0, 65.653 (2.514 to 9.693)NA (NA to NA)6.829 (3.549 to 10.804)
200 mg, n=74, 22, 255.499 (1.449 to 12.926)1.583 (0.455 to 3.542)5.350 (3.301 to 13.750)
225 mg, n=3, 0, 05.631 (4.815 to 5.642)NA (NA to NA)NA (NA to NA)
250 mg, n=18, 11, 05.059 (2.329 to 10.969)4.073 (2.184 to 8.768)NA (NA to NA)
300 mg, n=193, 5, 05.493 (1.620 to 13.335)2.837 (1.898 to 3.558)NA (NA to NA)
350 mg, n=0, 3, 0NA (NA to NA)4.084 (3.794 to 4.165)NA (NA to NA)
400 mg, n=19, 46, 07.322 (2.899 to 13.843)4.012 (1.459 to 9.675)NA (NA to NA)
450 mg, n=0, 1, 0NA (NA to NA)2.975 (NA to NA)NA (NA to NA)
500 mg, n=51, 121, 06.994 (0.931 to 13.412)3.974 (0.905 to 11.451)NA (NA to NA)
SecondaryApparent Clearance (CL/F) Based on the Concomitant AED Groups: Neutral, With EIAED, and With VPA

Individual serum LTG concentration data were subjected to population pharmacokinetic methodologies based on the concomitant AED groups. Clearance is defined as the volume of LTG per unit time eliminated from serum. Serum LTG concentration-time data files incorporating, where appropriate, records of LTG administration, participant demography, and concomitant medication were supplied to Clinical Pharmacokinetics Modelling and Simulation, Clinical Pharmacology, and Discovery Medicine (CPDM) by Clinical Data Management as NONMEM compatible .csv files.

Time frame:
Weeks 4, 7, 11, 15, 20, 24, and 28
Reported as:
Mean · Liters per hour
Apparent Clearance (CL/F) Based on the Concomitant AED Groups: Neutral, With EIAED, and With VPA
Liters per hourLTG-XR + NeutralLTG-XR + EIAEDsLTG-XR + VPA
Apparent Clearance (CL/F) Based on the Concomitant AED Groups: Neutral, With EIAED, and With VPA1.91 (1.73 to 2.09)2.07 (1.69 to 2.46)-0.698 (-0.96 to -0.441)
SecondaryApparent Volume of Distribution (V/F) for Participants in All Concomitant AED Groups Combined: Neutral, With EIAED, and With VPA

Individual serum LTG concentration data were subjected to population pharmacokinetic methodologies based on the concomitant AED groups. V/F is defined as the apparent volume in which a drug is distributed immediately after it has been injected intravenously and equilibrated between plasma and the surrounding tissues. Serum LTG concentration-time data files incorporating, where appropriate, records of LTG administration, participant demography, and concomitant medication were supplied to CPDM by Clinical Data Management as NONMEM compatible .csv files.

Time frame:
Weeks 4, 7, 11, 15, 20, 24, and 28
Reported as:
Mean · liters
Apparent Volume of Distribution (V/F) for Participants in All Concomitant AED Groups Combined: Neutral, With EIAED, and With VPA
litersLTG-XR + Neutral, EIAEDs, and VPA
Apparent Volume of Distribution (V/F) for Participants in All Concomitant AED Groups Combined: Neutral, With EIAED, and With VPA26.8 (7.40 to 46.6)
SecondaryAbsorption Rate (KA) for Participants in All Concomitant AED Groups Combined: Neutral, With EIAED, and With VPA

Individual serum LTG concentration data were subjected to population pharmacokinetic methodologies based on the concomitant AED groups. KA is defined as the rate at which a drug enters the body after administration. Serum LTG concentration-time data files incorporating, where appropriate, records of LTG administration, participant demography, and concomitant medication were supplied to CPDM by Clinical Data Management as NONMEM compatible .csv files.

Time frame:
Weeks 4, 7, 11, 15, 20, 24, and 28
Reported as:
Mean · 1/h
Absorption Rate (KA) for Participants in All Concomitant AED Groups Combined: Neutral, With EIAED, and With VPA
1/hLTG-XR + Neutral, EIAEDs, and VPA
Absorption Rate (KA) for Participants in All Concomitant AED Groups Combined: Neutral, With EIAED, and With VPA0.0325 (0.0105 to 0.0549)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LTG-XR Tablets—22/121 (18.2%)98/121 (81%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventLTG-XR Tablets
Hip fractureInjury, poisoning and procedural complications3/121
AtaxiaNervous system disorders2/121
ConvulsionNervous system disorders2/121
Status epilepticusNervous system disorders2/121
Acute myocardial infarctionCardiac disorders1/121
Balance disorderNervous system disorders1/121
Cardiac failure congestiveCardiac disorders1/121
Cerebrovascular accidentNervous system disorders1/121
ColitisGastrointestinal disorders1/121
DiverticulitisInfections and infestations1/121
Most frequent other events
Showing 10 of 22
Most frequent other events
EventLTG-XR Tablets
DizzinessNervous system disorders31/121
Balance disorderNervous system disorders25/121
FallInjury, poisoning and procedural complications22/121
HeadacheNervous system disorders21/121
TremorNervous system disorders20/121
FatigueNervous system disorders17/121
NauseaGastrointestinal disorders17/121
All rashSkin and subcutaneous tissue disorders14/121
AtaxiaNervous system disorders14/121
NasopharyngitisRespiratory, thoracic and mediastinal disorders12/121

Baseline characteristics

Age, Continuous
Age, Continuous(Years)LTG-XR Tablets
Mean72.5 ± 5.53
Gender
Gender(Participants)LTG-XR Tablets
Female59
Male62
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)LTG-XR Tablets
African American/African Heritage14
Asian - South East Asian Heritage2
White - Arabic/North African Heritage1
White - White/Caucasian/European Heritage105
08

Study locations

63 sites
  • GSK Investigational Site
    Birmingham, Alabama 35294-0021, United States
  • GSK Investigational Site
    Gilbert, Arizona 85234, United States
  • GSK Investigational Site
    Litchfield Park, Arizona 85340, United States
  • GSK Investigational Site
    Phoenix, Arizona 85003, United States
  • GSK Investigational Site
    Phoenix, Arizona 85013, United States
  • GSK Investigational Site
    Fresno, California 93710, United States
  • GSK Investigational Site
    Fullteron, California 92835, United States
  • GSK Investigational Site
    Irvine, California 92618, United States
  • GSK Investigational Site
    Los Angeles, California 90073, United States
  • GSK Investigational Site
    Pasadena, California 91106, United States
  • GSK Investigational Site
    Fort Collins, Colorado 80524, United States
  • GSK Investigational Site
    Newark, Delaware 19713, United States
  • GSK Investigational Site
    Gainesville, Florida 32610, United States
  • GSK Investigational Site
    Jacksonville, Florida 32224, United States
  • GSK Investigational Site
    Jacksonville, Florida 32266, United States
  • GSK Investigational Site
    Melbourne, Florida 32901, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Ponte Vedra Beach, Florida 32082, United States
  • GSK Investigational Site
    Sarasota, Florida 34233, United States
  • GSK Investigational Site
    Atlanta, Georgia 30309, United States
  • GSK Investigational Site
    Atlanta, Georgia 30322, United States
  • GSK Investigational Site
    Suwanee, Georgia 30024, United States
  • GSK Investigational Site
    Boise, Idaho 83702, United States
  • GSK Investigational Site
    Springfield, Illinois 62702, United States
  • GSK Investigational Site
    Fort Wayne, Indiana 46805, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46256, United States
  • GSK Investigational Site
    Wichita, Kansas 67214, United States
  • GSK Investigational Site
    Louisville, Kentucky 40202, United States
  • GSK Investigational Site
    Scarborough, Maine 4074, United States
  • GSK Investigational Site
    Burlington, Massachusetts 01805, United States
  • GSK Investigational Site
    Hopedale, Massachusetts 01747, United States
  • GSK Investigational Site
    Traverse City, Michigan 49684, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55422, United States
  • GSK Investigational Site
    St. Paul, Minnesota 55102, United States
  • GSK Investigational Site
    Chesterfield, Missouri 63017, United States
  • GSK Investigational Site
    Kansas City, Missouri 64111, United States
  • GSK Investigational Site
    Henderson, Nevada 89014, United States
  • GSK Investigational Site
    Camden, New Jersey 08103, United States
  • GSK Investigational Site
    Newark, New Jersey 07103, United States
  • GSK Investigational Site
    Summit, New Jersey 07901, United States
  • GSK Investigational Site
    Cedarhurst, New York 11516, United States
  • GSK Investigational Site
    Rochester, New York 14642, United States
  • GSK Investigational Site
    Schenectady, New York 12308, United States
  • GSK Investigational Site
    Columbus, Ohio 43210, United States
  • GSK Investigational Site
    Toledo, Ohio 43614, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73112, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19102, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15240, United States
  • GSK Investigational Site
    Sellersville, Pennsylvania 18960, United States
  • GSK Investigational Site
    Columbia, Tennessee 38401, United States
  • GSK Investigational Site
    Cordova, Tennessee 38018, United States
  • GSK Investigational Site
    Germantown, Tennessee 38139, United States
  • GSK Investigational Site
    Nashville, Tennessee 37232, United States
  • GSK Investigational Site
    Dallas, Texas 75214, United States
  • GSK Investigational Site
    Dallas, Texas 75230, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    Temple, Texas 76508, United States
  • GSK Investigational Site
    Richmond, Virginia 23298, United States
  • GSK Investigational Site
    Bremerton, Washington 98310, United States
  • GSK Investigational Site
    Madison, Wisconsin 53715, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53215, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2012, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2007
First posted
Aug 15, 2007
Start
Aug 2007
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Results first posted
Jan 13, 2012
Last update
Jan 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00516139
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 15, 2007
Start date
Aug 2007
Primary completion
Jul 2010
Completion
Jul 2010
Results posted
Jan 13, 2012
Last update
Jan 18, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamotrigine

Start the discussion